Skip to Main Content

Paper Details

Clinical Outcome of Prostate Cancer Patients with Germline DNA Repair Mutations: Retrospective Analysis from an International Study.
Eur Urol
95
2018
DNA Repair, DNA damage repair gene, DNA repair, PARP, PARPi, PARTICIPANTS, PATIENT, Patients, Prostate Cancer, abiraterone, docetaxel, enzalutamide, gBRCA1, gBRCA1/2m, gBRCA2m, gDDRm, mPC, metastatic prostate cancer, patients, platinum
Author NameAffiliation
Joaquin MateoThe Institute of Cancer Research, UK The Royal Marsden NHS Foundation Trust, UK Vall d'Hebron Institute of Oncology (VHIO)
Heather H ChengUniversity of Washington, USA Fred Hutchinson Cancer Research Center
Himisha BeltranWeill Cornell Medical College
Himisha BeltranWeill Cornell Medical College
Colin C PritchardUniversity of Washington, USA Fred Hutchinson Cancer Research Center
Raquel Perez-LopezThe Institute of Cancer Research, UK The Royal Marsden NHS Foundation Trust, UK Vall d'Hebron Institute of Oncology (VHIO)
Verena SailerWeill Cornell Medical College
David M NanusWeill Cornell Medical College
Scott T TagawaWeill Cornell Medical College
Heather ThorneThe University of Melbourne, Peter MacCallum Cancer Centre
Bruce MontgomeryUniversity of Washington, USA Fred Hutchinson Cancer Research Center
Suzanne CarreiraThe Institute of Cancer Research
Mark A RubinWeill Cornell Medical College, USA University of Bern
Mark A RubinWeill Cornell Medical College, USA University of Bern
Peter S NelsonUniversity of Washington, USA Fred Hutchinson Cancer Research Center
Peter S NelsonUniversity of Washington, USA Fred Hutchinson Cancer Research Center
Johann S de BonoThe Institute of Cancer Research, UK The Royal Marsden NHS Foundation Trust
  • 1 - 17

Datasets

Release 1.2